JAK Inhibitor Updates: Upadacitinib and the Level-Up Trial
Raj Chovatiya, MD, PhD, MSCI, and Lawrence Eichenfield, MD, review a recent trial comparing upadacitinib to dupilumab for patients with atopic dermatitis.
JAK Inhibitor Updates: Ruxolitinib Cream for Pediatric, Adolescent Eczema
Raj Chovatiya, MD, PhD, MSCI, and Lawrence Eichenfield, MD, discuss recent data assessing ruxolitinib cream for patients as young as 2 years old with atopic dermatitis.
Signs and Symptoms of Connective Tissue Disease
Amanda Mixon, PA-C, discusses how rheumatic diseases may first present in skin, ocular or gastric symptoms.
Connective Tissue Disease Brings Dermatology & Rheumatology Together
Amanda Mixon, PA-C, discusses the need to better bridge the rheumatology and dermatology care teams due to overlapping diseases.
Spesolimab Rapidly Improves QoL in Generalized Pustular Psoriasis
Patients in the spesolimab cohort demonstrated rapid improvements in DLQI scores compared with placebo, which were maintained through week 48.
What Makes JAK Inhibitors Safe in Dermatology
Matthew Zirwas, MD, reviews the clinical discrepancies of certain JAK-targeting therapies and their role in dermatology patient outcomes.
Potential JAK Inhibitor Combination Regimens in Dermatology
Matthew Zirwas, MD, discusses the prospect of pairing JAK inhibitors like ruxolitinib cream with other disease-targeting options for conditions including vitiligo and alopecia areata.
Bimekizumab Response is Sustained Over 4 Years in Plaque Psoriasis
Responses were highly durable throughout 4 years of bimekizumab treatment.
Therapies in Development for Hidradenitis Suppurativa
Jennifer L. Hsiao, MD, reviews the rapidly growing inventory of investigational drugs for HS.
"Prednisone Without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Matthew Zirwas, MD, explains why he believes agents like ruxolitinib cream and upadacitinib have become the optimal treatments for atopic dermatitis, hidradenitis suppurativa, and more.
Halobetasol Propionate, Tazarotene Lotion Demonstrates Clinically Significant Skin Clearance in Hyperkeratotic Psoriasis
Significantly greater improvements were reported at week 2, which were sustained through week 12, in patients receiving the halobetasol propionate/tazarotene lotion compared with the vehicle cohort.
Brodalumab Demonstrates Efficacy, Safety in Moderate to Severe Psoriasis
Overall, 189 (74.1%) patients treated with brodalumab achieved PASI 75, 133 (52.2%) achieved PASI 90, and 98 (38.4%) achieved PASI 100.
Lisa Swanson, MD: Strategies to Combat Burnout
Lisa Swanson, MD, explains how building resiliency is crucial for coping with burnout.
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
Jennifer L. Hsiao, MD, discusses what the anticipated JAK inhibitors may provide to patients with HS if FDA-approved in the coming years.
Unraveling Atopic Dermatitis, with Lisa Swanson, MD
Lisa Swanson, MD, discusses the pathogenesis of atopic dermatitis and why she does not recommend elimination diets for her pediatric patients.
The JAK Inhibitor Safety Conversation
Matthew Zirwas, MD, provides advice to dermatologists discussing the safety of JAK inhibitor therapies due to their controversial black box warning.
Secukinumab and Bimekizumab for Hidradenitis Suppurativa
Patients with HS are getting a long-awaited influx of targeted therapies. Jennifer L. Hsiao, MD, discusses their immediate impact.
FDA Approves Tirbanibulin for Actinic Keratosis on Larger Areas of Face, Scalp
The new approval expands the treatment area by 4 times the previously approved area—from 25 cm2 to 100 cm2.
Advancements in Pediatric Psoriasis Treatment, with Lisa Swanson, MD
Lisa Swanson, MD, discusses the recent advancements in pediatric dermatology and emphasizes the importance of correctly diagnosing conditions to improve patient outcomes.
Heather Woolery-Lloyd, MD, FAAD: Interview on Common Skin of Color Dermatoses
An interview on the SDPA 2022 presentation of Dr. Woolery-Lloyd in which she discusses dermatoses affecting patients of color.
Orit Markowitz, MD: Artificial Intelligence, Patient Knowledge on Skin Cancer
A discussion with Dr. Markowitz on her presentation from SDPA 2022, during which she described various gaps in knowledge on skin health and future innovations she hoped to see.
Ruxolitinib Cream Improves Atopic Dermatitis Pain, Anxiety and Depression Over 52 Weeks
New long-term phase 3 data show adults and adolescents both improved measures of quality of life when treated with either of 2 doses of ruxolitinib cream.
Orit Markowitz, MD: How to Distinguish Skin Cancer from Less Dangerous Skin Conditions
An interview with Dr. Markowitz on her presentation at SDPA 2022 presentation entitled ‘Skin of Color,’ regarding differentiating skin cancer from other conditions.
Ted Rosen, MD: Seborrheic Dermatitis, Tinea Versicolor, Other Conditions Resembling Vitiligo
An interview with Dr. Rosen regarding his SDPA 2022 presentation on dermatologic conditions with white spots that are often misdiagnosed as vitiligo.
Ted Rosen, MD: Potential Reasons for Misdiagnosis of White Spots as Vitiligo
A discussion with Dr. Rosen on one of his SPDA 2022 presentations, highlighting his reason for choosing the topic and exploring vitiligo misdiagnosis.
Dupilumab Maintains Atopic Dermatitis Clearance, Symptom Benefit Over 4 Years
Findings from the ongoing LIBERTY AD OLE trial show the sustained long-term effect of the biologic therapy for eczema.
Jennifer Orozco, DMSc, PA-C: Resources for Physician Associates and ‘PAs Go Beyond’
A discussion with Dr. Orozco on her SDPA 2022 presentation, discussing useful resources for physicians and PAs looking to get involved in the PAs Go Beyond campaign.
Rajani Katta, MD: Chronic Inflammatory Skin Disease and Obesity Comorbidities
In her SDPA 2022 presentation interview, Dr. Katta explores gaps in knowledge regarding the connection between skin disease and dietary health, as well as ways to address these concerns.
Rajani Katta, MD: Connection Between Obesity, Dietary Health, and Dermatology
Dr. Katta’s interview regarding her SDPA 2022 presentation, during which she discusses the topic of obesity, dietary health, and their relationship with skin conditions like psoriasis.
Patients with Intertriginous Area Psoriasis Frequently Report Embarrassment, Sexual Distress
Online survey results show adults with psoriasis in specific areas may be treating and monitoring disease without clinician guidance—sometimes out of embarassment.
